Publicaciones (86) Publicaciones de YOLANDA ALADRO BENITO

2024

  1. Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis

    Frontiers in Neurology , Vol. 15

  2. Sufficiency for PSS tracking gait disorders in multiple sclerosis: A managerial perspective

    Heliyon, Vol. 10, Núm. 9

2023

  1. Abnormal functional connectivity in radiologically isolated syndrome: A resting-state fMRI study

    Multiple Sclerosis Journal, Vol. 29, Núm. 11-12, pp. 1393-1405

  2. MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate

    Biomedicines, Vol. 11, Núm. 10

  3. Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study

    Neurology Perspectives, Vol. 3, Núm. 4

  4. Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response

    Frontiers in Immunology, Vol. 14

  5. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  6. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

    Frontiers in immunology, Vol. 13, pp. 842354

  2. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 59

  3. Endarterectomy, Stenting, or Medical Treatment for Symptomatic Carotid Near-Occlusion: Results from CAOS, a Multicenter Registry Study

    American Journal of Neuroradiology, Vol. 43, Núm. 9, pp. 1304-1310

  4. Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate

    Scientific Reports, Vol. 12, Núm. 1

  5. Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis

    Multiple Sclerosis and Related Disorders

  6. Patients' self-assessment of essential tremor severity by a validated scale: A useful tool in telemedicine?

    Parkinsonism and Related Disorders, Vol. 96, pp. 22-28

  7. Risk and prognostic factors for SARS-CoV-2 infection in Spanish population with multiple sclerosis during the first five waves

    Frontiers in Neurology, Vol. 13

  8. microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate

    Frontiers in Immunology, Vol. 13

2021

  1. Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment

    Multiple Sclerosis and Related Disorders, Vol. 49

  2. Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

    Neurology(R) neuroimmunology & neuroinflammation, Vol. 8, Núm. 2

  3. Genetic variation in NDFIP1 modifies the metabolic patterns in immune cells of multiple sclerosis patients

    Scientific Reports, Vol. 11, Núm. 1

  4. Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis

    Frontiers in Immunology, Vol. 12